HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BR101549

an agonist of PPARgamma

Also Known As:

ethyl 2-(2-butyl-6-oxo-1-((4-(2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl)phenyl)methyl)-4-propan-2-ylpyrimidin-5-yl)acetate

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        BR101549: 2
  - Pyrimidines: 510
    - BR101549: 2

Experts

1.	Chin, Jungwook: 2 articles (01/2019 - 01/2019)
2.	Choi, Hyukjoon: 2 articles (01/2019 - 01/2019)
3.	Choung, Wonken: 2 articles (01/2019 - 01/2019)
4.	Hong, Eunmi: 2 articles (01/2019 - 01/2019)
5.	Jang, Su Min: 2 articles (01/2019 - 01/2019)
6.	Jang, Tae-Ho: 2 articles (01/2019 - 01/2019)
7.	Jung, Kyungjin: 2 articles (01/2019 - 01/2019)
8.	Kim, Kyung-Hee: 2 articles (01/2019 - 01/2019)
9.	Kim, Seong Heon: 2 articles (01/2019 - 01/2019)
10.	Kim, Woo Sik: 2 articles (01/2019 - 01/2019)

Related Diseases

1.

Type 2 Diabetes Mellitus (MODY)

01/01/2019 - "Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR."
01/01/2019 - "As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach. "

Related Drugs and Biologics

1.	compound 18